About cellectar biosciences inc - CLRB
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.
CLRB At a Glance
Cellectar Biosciences, Inc.
100 Campus Drive
Florham Park, New Jersey 07932
| Phone | 1-608-441-8120 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -21,791,037.00 | |
| Sector | Health Technology | Employees | 11 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CLRB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.56 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.14 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.128 |
CLRB Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,981,003.364 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CLRB Liquidity
| Current Ratio | 2.956 |
| Quick Ratio | 2.956 |
| Cash Ratio | 2.778 |
CLRB Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -107.737 |
| Return on Equity | -170.27 |
| Return on Total Capital | -210.974 |
| Return on Invested Capital | -165.618 |
CLRB Capital Structure
| Total Debt to Total Equity | 4.129 |
| Total Debt to Total Capital | 3.965 |
| Total Debt to Total Assets | 2.735 |
| Long-Term Debt to Equity | 3.86 |
| Long-Term Debt to Total Capital | 2.995 |